Table 3.
Outcome of first-line treatment.
| Response | All patients (n=243) | Other treatment* (n=26) | (R)MAD (n=170) | (R)MADD (n=47) |
|---|---|---|---|---|
| Complete response | 143 (58.8%) | 10 (38.5%) | 96 (56.5%) | 37 (78.7%) |
| Partial response | 34 (14.0%) | 6 (23.1%) | 23 (13.5%) | 5 (10.6%) |
| Stable disease | 17 (7.0%) | 5 (19.2%) | 11 (6.5%) | 1 (2.1%) |
| Progression disease | 49 (20.2%) | 5 (19.2%) | 40 (23.5%) | 4 (8.5%) |
| Overall response rate | 177 (72.8%) | 16 (61.5%) | 119 (70.0%) | 42 (89.3%) |
*Other treatment included HD-MTX single regimen, Temozolomide, Pemetrexed, lenalidomide regimen; (R)MAD, (Rituximab)+ Methotrexate +Ara-C +Dexamethasone; (R)MADD, (Rituximab)+ Methotrexate+ Ara-C+ Dexamethasone+ liposomal doxorubicin.